Related Experiment Video
Updated: Jan 16, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
An Argument for Decentralized Clinical Trials in Gynecologic Oncology
Shilpa Mokshagundam1, Michaela E McGree1, Angela J Fought1
1Departments of Obstetrics and Gynecology, Quantitative Health Sciences, and Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract:
To evaluate factors that may influence clinical trial enrollment, we compared demographics, clinical characteristics, and patient-reported social determinants of health for patients with advanced ovarian cancer who were approached for enrollment in a prehabilitation trial. Although no significant differences were found in the majority of demographic and clinical characteristics, distance to study institution was associated with decision to enroll; 21.9% of enrolled compared with 42.2% of not enrolled patients lived 200 miles or more from the study institution (P< .05). In addition, compared with not enrolled patients, enrolled patients were more likely to be receiving neoadjuvant chemotherapy within the study institution compared with a nonstudy institution clinician (81.2% vs 53.1%, P=.02). These findings highlight barriers to enrollment that can be addressed through decentralization of clinical trials.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence studies: Biowaivers
Treatment Resistant Cancers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

